Immunogenicity and Safety of vYF, a Yellow Fever Vaccine — A Phase 2 Trial

Overview of attention for article published in New England Journal of Medicine, April 2026

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

news: 3 news outlets
twitter: 28 X users

bluesky: 16 Bluesky users

Readers on

mendeley: 16 Mendeley

So far, Altmetric has seen 20 Bluesky posts from 16 Bluesky users, with an upper bound of 81,476 followers.

Phase 2 trial: vYF, a new yellow fever vaccine, tested in 635 adults aged 18–60. Results at year 1: strong immune responses and safety comparable to YF-VAX. PMID:41950474, N Engl J Med 2026, @NEJM https://doi.org/10.1056/NEJMoa2505665 #Medsky #Pharmsky #R…

I'm curious to see how this trial advances! https://bsky.app/profile/did:plc:mgwrki6irihfcatu2v347soc/post/3mjkcigymuk2v

RP @nejm.org: In a phase 2 trial, a new yellow fever vaccine grown in Vero cells was shown to elicit immunogenicity similar to that of the standard yellow fever vaccine. Full trial results and Research Summary: nej.md/4sq5Lay #InfectiousDisease

Next-generation yellow fever vaccine vYF demonstrates similar immunogenicity and safety to licensed YF-VAX in Phase 2 trial. by Feroldi E, Mulligan MJ (...) Frago C et 18 al. in N Engl J Med #MedSky 👉 get more here 📖 read the article: https://www.nej…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity, including 16 additional Bluesky posts.